These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18496682)

  • 1. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
    Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
    Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
    Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
    Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
    Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
    Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
    Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
    Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
    Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
    Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
    Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
    Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
    [No Abstract]   [Full Text] [Related]  

  • 7. The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
    Hopkins AM; O'Doherty CE; Foster DJ; Suppiah V; Upton RN; Spargo LD; Cleland LG; Proudman SM; Wiese MD
    J Clin Pharm Ther; 2014 Oct; 39(5):555-60. PubMed ID: 25040563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.
    Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Vieira de Lara D; Zubiaur P; Koller D; Mejía G; Abad-Santos F
    J Psychopharmacol; 2019 Apr; 33(4):522-531. PubMed ID: 30789308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis.
    Machaj F; Rosik J; Szostak B; Malinowski D; Safranow K; Olędzka G; Wiechec E; Pawlik A
    Clin Rheumatol; 2023 Sep; 42(9):2477-2483. PubMed ID: 37289314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
    Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
    J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
    Laika B; Leucht S; Heres S; Schneider H; Steimer W
    Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.
    Makarem YS; Hareedy MS; Hassanien M; Ahmed EA; Hetta HF; Mohamed AA
    Pharmacogenomics; 2021 Dec; 22(18):1201-1209. PubMed ID: 34747629
    [No Abstract]   [Full Text] [Related]  

  • 13. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
    Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
    J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
    Czerwensky F; Leucht S; Steimer W
    Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.
    Łączna M; Malinowski D; Paradowska-Gorycka A; Safranow K; Dziedziejko V; Pawlik A
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1673-1678. PubMed ID: 34160668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.
    Bilasy SE; Essawy SS; Mandour MF; Ali EA; Zaitone SA
    Pharmacol Rep; 2015 Feb; 67(1):102-14. PubMed ID: 25560583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
    Dziedziejko V; Kurzawski M; Safranow K; Chlubek D; Pawlik A
    Pharmacogenomics; 2011 Jan; 12(1):41-7. PubMed ID: 21174621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.
    Han XM; Ouyang DS; Chen XP; Shu Y; Jiang CH; Tan ZR; Zhou HH
    Br J Clin Pharmacol; 2002 Nov; 54(5):540-3. PubMed ID: 12445035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
    Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
    Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
    Kiely PD; Johnson DM
    Rheumatology (Oxford); 2002 Jun; 41(6):631-7. PubMed ID: 12048288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.